Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.
about
The role of FLT3 in haematopoietic malignanciesStructural and functional alterations of FLT3 in acute myeloid leukemiaPrevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology GroupMicro-RNAs and copy number changes: new levels of gene regulation in acute myeloid leukemiaDownstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implicationsPrognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B studyCross-platform analysis of cancer microarray data improves gene expression based classification of phenotypesSorafenib in combination with low-dose-homoharringtonine as a salvage therapy in primary refractory FLT3-ITD-positive AML: a case report and review of literatureThe Potential of Vitamin D-Regulated Intracellular Signaling Pathways as Targets for Myeloid Leukemia TherapyAllogeneic stem cell transplantation in first complete remissionMolecular prognostic factors in cytogenetically normal acute myeloid leukemiaGenomics of acute myeloid leukemiaProgress in acute myeloid leukemiaAn overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatmentFLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?The prognostic and functional role of microRNAs in acute myeloid leukemiaFLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications.Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B studyFavorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia.Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemiaValidation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemiaInternal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic LeReceptor Signaling Directs Global Recruitment of Pre-existing Transcription Factors to Inducible ElementsSecondary mutations as mediators of resistance to targeted therapy in leukemiaPrognostic implications of the presence of FLT3 mutations in patients with acute myeloid leukemiaPhase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemiaMutant FLT3 signaling contributes to a block in myeloid differentiationFLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitationsClinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise reviewSurvey of activated FLT3 signaling in leukemiaEvaluation of the antitumor effects of BPR1J-340, a potent and selective FLT3 inhibitor, alone or in combination with an HDAC inhibitor, vorinostat, in AML cancerTargeting oncoprotein stability overcomes drug resistance caused by FLT3 kinase domain mutationsMll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemiasForced expression of the DEK-NUP214 fusion protein promotes proliferation dependent on upregulation of mTORC/EBP and DEK coordinately regulate myeloid differentiation
P2860
Q24319174-BD546803-E878-4EB3-87D1-6E4A0ADE9A89Q24338964-BB74522A-84B5-4BDB-AD4F-29AD75449C37Q24602856-8F73E598-278E-4036-ACFA-4D93A18FBAD9Q24612217-0511837F-FC57-44C8-BF0B-79656341B1A9Q24617091-E53A38BE-A335-4D1E-9EB7-7769EF68552EQ24643738-1EB88D3F-0996-4767-BE1F-69AFCB0E49E6Q24811346-518343A9-A9A8-44C1-BD2A-EC4DFBD6A5F7Q26765296-8D4E619B-E1AA-42D5-9047-1669732CAAF3Q26799596-BC8056EC-EEA1-4FE9-86DD-D1866C270564Q26996818-1FD66208-E238-42F3-880F-6D19CE48F2EFQ26998811-B3D0B103-7838-4EF4-B829-A09F503BE1F6Q27021548-C5A3B0EE-8B68-47A9-BA58-AA0EB2497911Q27024006-FE28ADA9-5625-4D81-9638-C8D71FCA498AQ27027207-CE1B8C4E-C9E9-4425-A523-4DDF4FF12218Q27028163-71353B86-1CFB-47DF-A226-6F345260BA88Q27693865-0A1CBD52-8407-434A-A1BA-145810C25DBAQ27851415-1CC8FF62-723F-4C05-BD8A-54B6DB8C1F0EQ27851436-B5A8C73C-44DE-415C-9803-4BE4F3862EF7Q27851545-156C24BE-5E41-4684-A32E-CA10970E3E3BQ27851621-7096078F-8F38-49B0-8F14-49C7C97994EFQ27851642-AE31EE95-9F51-4714-A5EB-A415F5E4285FQ27851713-57092FFA-7ED4-4B53-A4D8-CCF489C17F8CQ27851767-DE219226-0141-4844-900E-C0BABAD429AEQ27851839-A3E914F1-4F89-4BC3-A897-9C1920EE0DA2Q27852520-EDF1A402-83BF-4FDD-81D7-A911CC1447BEQ27853019-B751DAC9-2F99-4FE4-A131-E1681C70D1B6Q27853031-F005538F-9977-4BC3-BF76-A780261F2C87Q28079289-A942F09E-C8D7-42D6-919F-0A52FBE4DC0DQ28087213-A5C2ACD2-F55E-44B5-B661-D307A4649783Q28186429-12C207D3-B179-43B9-AD41-D13226A9C8FCQ28271726-9B3D236B-7621-41FB-BBC0-9E3C08C189E4Q28279890-0CD70E69-058C-4A71-B7BE-95B973D036B4Q28289859-9B1B99EB-2B4D-4DD3-A82D-08B0B5215630Q28301344-7003E270-E01D-47EE-94D0-FB48A7FAB396Q28477934-70A4767E-1BD6-4310-87D0-E092FAAD9611Q28538435-886A7081-2B1B-4E5B-943F-664502F2B12AQ28539032-04362CE3-8FAA-4D9D-A3DD-CD81406881E0Q28594733-782AE0CD-9CC4-4200-B38F-4596D65E6ED6Q29037521-9B2D3783-DFB0-4A93-B589-7FC2614DE43CQ29041284-7ABC6E80-E985-4384-9A01-7449E61ED52A
P2860
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Analysis of FLT3-activating mu ...... subgroups with poor prognosis.
@ast
Analysis of FLT3-activating mu ...... subgroups with poor prognosis.
@en
Analysis of FLT3-activating mu ...... subgroups with poor prognosis.
@nl
type
label
Analysis of FLT3-activating mu ...... subgroups with poor prognosis.
@ast
Analysis of FLT3-activating mu ...... subgroups with poor prognosis.
@en
Analysis of FLT3-activating mu ...... subgroups with poor prognosis.
@nl
prefLabel
Analysis of FLT3-activating mu ...... subgroups with poor prognosis.
@ast
Analysis of FLT3-activating mu ...... subgroups with poor prognosis.
@en
Analysis of FLT3-activating mu ...... subgroups with poor prognosis.
@nl
P2093
P50
P1433
P1476
Analysis of FLT3-activating mu ...... subgroups with poor prognosis.
@en
P2093
Andreas Neubauer
Brigitte Mohr
Christian Thiede
Christine Steudel
Markus Ritter
Markus Schaich
Martin Wermke
Thomas Illmer
Ulrike Schäkel
P304
P356
10.1182/BLOOD.V99.12.4326
P407
P577
2002-06-01T00:00:00Z